Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTP-002/FTP-501 combination for glabellar lines
2023-507249-27-00Phase 2Completed
- Sponsor
- Fastox Pharma S.A.
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dantrolene sodium, FTP-501, botulinum toxin type A and dantrolene in glabellar furrowing (3 arms), sponsored by Fastox Pharma S.A. Started May 2024; status: completed.
02
Drugs
dantrolene sodiumFTP-501botulinum toxin type Adantrolene
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2023-507249-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507249-27-00.